Comment
doi: 10.1016/S1470-2045(16)00025-5.
Epub 2016 Mar 11.
ALK inhibitors: plateauing systemic and intracranial activity?
Affiliations
- PMID: 26973321
- DOI: 10.1016/S1470-2045(16)00025-5
Item in Clipboard
Comment
ALK inhibitors: plateauing systemic and intracranial activity?
Lancet Oncol.
2016 Apr.
No abstract available
Comment on
-
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Lancet Oncol. 2016 Apr;17(4):452-463. doi: 10.1016/S1470-2045(15)00614-2. Epub 2016 Mar 11. Lancet Oncol. 2016. PMID: 26973324 Free PMC article. Clinical Trial.
Similar articles
-
Ascending role of next-generation ALK inhibitors.Lancet Oncol. 2017 Jul;18(7):837-839. doi: 10.1016/S1470-2045(17)30338-8. Epub 2017 Jun 9. Lancet Oncol. 2017. PMID: 28602777 No abstract available.
-
Crizotinib in ALK-positive lung cancer.Lancet Oncol. 2012 Oct;13(10):962-3. doi: 10.1016/S1470-2045(12)70375-3. Epub 2012 Sep 4. Lancet Oncol. 2012. PMID: 22954506 No abstract available.
-
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.J Clin Oncol. 2015 Jun 10;33(17):1881-8. doi: 10.1200/JCO.2014.59.0539. Epub 2015 Jan 26. J Clin Oncol. 2015. PMID: 25624436 Free PMC article.
-
New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.Curr Treat Options Oncol. 2015 Oct;16(10):49. doi: 10.1007/s11864-015-0367-z. Curr Treat Options Oncol. 2015. PMID: 26318457 Review.
-
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?Cancer Metastasis Rev. 2015 Dec;34(4):797-805. doi: 10.1007/s10555-015-9592-y. Cancer Metastasis Rev. 2015. PMID: 26342831 Free PMC article. Review.
Cited by
-
De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.Lung Cancer. 2016 Sep;99:17-22. doi: 10.1016/j.lungcan.2016.06.006. Epub 2016 Jun 14. Lung Cancer. 2016. PMID: 27565908 Free PMC article.
-
Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.J Thorac Dis. 2017 Sep;9(9):2812-2818. doi: 10.21037/jtd.2017.08.79. J Thorac Dis. 2017. PMID: 29221246 Free PMC article. No abstract available.
-
Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib.Nat Commun. 2017 Jun 8;8:15761. doi: 10.1038/ncomms15761. Nat Commun. 2017. PMID: 28594000 Free PMC article.
-
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.J Thorac Oncol. 2017 May;12(5):878-883. doi: 10.1016/j.jtho.2016.12.026. Epub 2017 Jan 16. J Thorac Oncol. 2017. PMID: 28104537 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
